Bausch Health Companies Inc.

NYSE:BHC Stock Report

Market Cap: US$2.7b

Bausch Health Companies Future Growth

Future criteria checks 3/6

Bausch Health Companies is forecast to grow earnings and revenue by 95.6% and 1.9% per annum respectively while EPS is expected to grow by 104.5% per annum.

Key information

95.6%

Earnings growth rate

104.5%

EPS growth rate

Pharmaceuticals earnings growth23.7%
Revenue growth rate1.9%
Future return on equityn/a
Analyst coverage

Good

Last updated17 Jul 2024

Recent future growth updates

Recent updates

The Market Doesn't Like What It Sees From Bausch Health Companies Inc.'s (NYSE:BHC) Revenues Yet As Shares Tumble 25%

May 21
The Market Doesn't Like What It Sees From Bausch Health Companies Inc.'s (NYSE:BHC) Revenues Yet As Shares Tumble 25%

Why Bausch Health Stock Plunged After Posting First-Quarter 2024 Results

May 07

Bausch Health: A Timely Divestiture Is The Key To An Higher Valuation

Feb 24

Bausch Health: $20bn Debt Is A Mighty Elephant In The Room

Nov 30

Does Bausch Health Companies (NYSE:BHC) Have A Healthy Balance Sheet?

Nov 01
Does Bausch Health Companies (NYSE:BHC) Have A Healthy Balance Sheet?

Bausch Health's Debt Dilemma: Strategic Decisions And Financial Metrics

Sep 24

Is Bausch Health Companies (NYSE:BHC) A Risky Investment?

Jul 24
Is Bausch Health Companies (NYSE:BHC) A Risky Investment?

Bausch + Lomb: $2.5bn M&A Deal Shows It Hasn't Learned From Parent's Mistakes

Jul 06

What To Do After Bausch Health Stock Plunged By Nearly 9% Again

Jun 07

Bausch Health Companies (NYSE:BHC) Has No Shortage Of Debt

Apr 18
Bausch Health Companies (NYSE:BHC) Has No Shortage Of Debt

Bausch Health: A Basket Case Of A Business Only A Hedge Fund Can Bail Out

Dec 30

Bausch Health acne lotion Arazlo available in Canada under public drug plans

Dec 22

Bausch Health: Things To Consider Before Investing

Dec 11

Bausch Health Companies (NYSE:BHC) Strong Profits May Be Masking Some Underlying Issues

Nov 10
Bausch Health Companies (NYSE:BHC) Strong Profits May Be Masking Some Underlying Issues

Bausch Health Companies Q3 2022 Earnings Preview

Nov 02

Bausch Health: Long-Term Need To Place Stops For Protection

Sep 28

Bausch Health Companies: Equity Stub Would Benefit From Ambitious Spinoff

Sep 21

Bausch Health sheds 10% as FDA grants tentative approval for Xifaxan generic

Sep 08

Bausch Health begin offers to exchange debt up to $4B

Aug 31

Earnings and Revenue Growth Forecasts

NYSE:BHC - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202610,008432N/A1,4396
12/31/20259,6863861,3481,4647
12/31/20249,3991441,0411,4468
3/31/20248,966-4557851,089N/A
12/31/20238,757-5927601,032N/A
9/30/20238,542-9638931,117N/A
6/30/20238,350-186-665-428N/A
3/31/20238,150-357-773-511N/A
12/31/20228,124-225-996-728N/A
9/30/20228,127254-1,434-1,179N/A
6/30/20228,19243384648N/A
3/31/20228,325-407648920N/A
12/31/20218,434-9481,1431,426N/A
9/30/20218,451-1,1701,5121,796N/A
6/30/20218,478-1,2871,1901,488N/A
3/31/20218,042-1,0189881,293N/A
12/31/20208,027-5608021,111N/A
9/30/20208,038-1,923641951N/A
6/30/20208,109-2,0438991,210N/A
3/31/20208,597-1,8881,0461,349N/A
12/31/20198,601-1,7881,2231,501N/A
9/30/20198,498-6161,3291,586N/A
6/30/20198,425-9171,3861,593N/A
3/31/20198,401-1,6191,2411,476N/A
12/31/20188,380-4,1481,2661,501N/A
9/30/20188,422-3,2911,5171,760N/A
6/30/20188,505-1,6401701,728N/A
3/31/20188,610-8052601,774N/A
12/31/20178,7242,404N/A2,290N/A
9/30/20178,9641,376N/A2,224N/A
6/30/20179,224-1,143N/A2,304N/A
3/31/20179,411-1,407N/A2,484N/A
12/31/20169,674-2,409N/A2,087N/A
9/30/201610,024-2,280N/A2,172N/A
6/30/201610,332-1,013N/A2,360N/A
3/31/201610,644-764N/A2,323N/A
12/31/201510,442-292N/A2,257N/A
9/30/20159,906596N/A2,476N/A
6/30/20159,175822N/A2,336N/A
3/31/20158,4841,001N/A2,302N/A
12/31/20148,200881N/A2,312N/A
9/30/20148,043502N/A1,759N/A
6/30/20147,529-746N/A1,342N/A
3/31/20146,583-861N/A1,271N/A
12/31/20135,766-866N/A1,042N/A
9/30/20134,626-1,079N/A830N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: BHC is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.4%).

Earnings vs Market: BHC is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: BHC is expected to become profitable in the next 3 years.

Revenue vs Market: BHC's revenue (1.9% per year) is forecast to grow slower than the US market (8.6% per year).

High Growth Revenue: BHC's revenue (1.9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if BHC's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.